PD-L1 CPS ist der primäre prädiktive Biomarker für Pembrolizumab in rezidivierenden/metast...
Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.
| ID | BMA-PDL1-CPS-HNSCC |
|---|---|
| Art | Therapeutische Relevanz |
| Status | reviewed 2026-05-07 | actionability review required |
| Erkrankungen | DIS-HNSCC |
| Quellen | SRC-ESMO-HNSCC-2020 SRC-NCCN-HNSCC-2025 |
Fakten zur Handlungsfähigkeit
| Biomarker | BIO-PDL1-CPS |
|---|---|
| Erkrankung | DIS-HNSCC |
| ESCAT-Stufe | IA |
| Empfohlene Kombinationen | pembrolizumab monotherapy (CPS≥20 1L per SRC-NCCN-HNSCC-2025, SRC-ESMO-HNSCC-2020), pembrolizumab + platinum + 5-FU (CPS≥1 1L per SRC-NCCN-HNSCC-2025) |
| Zusammenfassung der Beweise | PD-L1 CPS is the primary predictive biomarker for pembrolizumab in recurrent/metastatic HNSCC (KEYNOTE-048). Two threshold-stratified eligibility bands: CPS ≥1 — pembrolizumab + platinum + 5-FU 1L (superior to EXTREME regimen in CPS≥1 population); CPS ≥20 — pembrolizumab monotherapy 1L (preferred over chemo in high-expressors; mOS 14.9 mo). Both are FDA-approved and NCCN/ESMO Category 1 recommendations. Testing by IHC 22C3. Threshold selection is performed by the algorithm layer (ALGO-HNSCC-RM-1L); this BMA entry surfaces ESCAT tier context for tumor-board discussion only. |
Anmerkungen
Variant_qualifier null — dual-threshold gating (CPS≥1 for combo, CPS≥20 for mono) is enforced by the algorithm/indication layer, not this BMA cell. KEYNOTE-048 source stub not yet ingested; citing NCCN/ESMO as proxies.
Verwendet von
Keine Rückverweise im YAML-Korpus gefunden.